Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 5;12(3):229.
doi: 10.3390/pharmaceutics12030229.

Benefits and Prerequisites Associated with the Adoption of Oral 3D-Printed Medicines for Pediatric Patients: A Focus Group Study among Healthcare Professionals

Maria Rautamo  1   2   3 , Kirsi Kvarnström  1   2 , Mia Sivén  2 , Marja Airaksinen  2 , Pekka Lahdenne  4 , Niklas Sandler  3
Affiliations

Benefits and Prerequisites Associated with the Adoption of Oral 3D-Printed Medicines for Pediatric Patients: A Focus Group Study among Healthcare Professionals

Maria Rautamo et al. Pharmaceutics. .

Abstract

The utilization of three-dimensional (3D) printing technologies as innovative manufacturing methods for drug products has recently gained growing interest. From a technological viewpoint, proof-of-concept on the performance of different printing methods already exist, followed by visions about future applications in hospital or community pharmacies. The main objective of this study was to investigate the perceptions of healthcare professionals in a tertiary university hospital about oral 3D-printed medicines for pediatric patients by means of focus group discussions. In general, the healthcare professionals considered many positive aspects and opportunities in 3D printing of pharmaceuticals. A precise dose as well as personalized doses and dosage forms were some of the advantages mentioned by the participants. Especially in cases of polypharmacy, incorporating several drug substances into one product to produce a polypill, personalized regarding both the combination of drug substances and the doses, would benefit drug treatments of several medical conditions and would improve adherence to medications. In addition to the positive aspects, concerns and prerequisites for the adoption of 3D printing technologies at hospital settings were also expressed. These perspectives are suggested by the authors to be focus points for future research on personalized 3D-printed drug products.

Keywords: 3D printing; 3D-printed medicines; children; focus group study; healthcare professionals; hospital pharmacy; pediatrics; personalized medication.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Themes of categories and subcategories identified in the focus group discussions of healthcare professionals on 3D-printed drug products.
Figure 2
Figure 2
Identified subcategories of prerequisites for the adoption of 3D-printed drug products for pediatric patients at hospital wards.
See this image and copyright information in PMC

References

    1. Preis M., Breitkreutz J., Sandler N. Perspective: Concepts of printing technologies for oral film formulations. Int. J. Pharm. 2015;494:578–584. doi: 10.1016/j.ijpharm.2015.02.032. - DOI - PubMed
    1. El Aita I., Breitkreutz J., Quodbach J. On-demand manufacturing of immediate release levetiracetam tablets using pressure-assisted microsyringe printing. Eur. J. Pharm. Biopharm. 2019;134:29–36. doi: 10.1016/j.ejpb.2018.11.008. - DOI - PubMed
    1. Khaled S.A., Alexander M.R., Wildman R.D., Wallace M.J., Sharpe S., Yoo J., Roberts C.J. 3D extrusion printing of high drug loading immediate release paracetamol tablets. Int. J. Pharm. 2018;538:223–230. doi: 10.1016/j.ijpharm.2018.01.024. - DOI - PubMed
    1. Goyanes A., Madla C.M., Umerji A., Duran Piñeiro G., Giraldez Montero J.M., Lamas Diaz M.J., Gonzalez Barcia M., Taherali F., Sánchez-Pintos P., Couce M.-L., et al. Automated therapy preparation of isoleucine formulations using 3D printing for the treatment of MSUD: First single-centre, prospective, crossover study in patients. Int. J. Pharm. 2019;567:118497. doi: 10.1016/j.ijpharm.2019.118497. - DOI - PubMed
    1. Sjöholm E., Sandler N. Additive manufacturing of personalized orodispersible warfarin films. Int. J. Pharm. 2019;564:117–123. doi: 10.1016/j.ijpharm.2019.04.018. - DOI - PubMed

LinkOut - more resources